Skip to main content

Advertisement

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

Article metrics

  • 1581 Accesses

Introduction

We conducted a phase II trial to define the safety, the efficacy, the pathological response rate and survival associated with four cycles DXR-GMZ administered every 3 weeks followed by surgery, then four cycles of FAC50 as a primary therapy in MBC.

Method

Patients with histologically or cytologically confirmed MBC, ECOG PS: 2 and adequate hepatic, renal and cardiac functions were eligible. Prior chemotherapy was not allowed.

Results

Fifty-one patients were included, after signing an informed consent. Median age was 47.07 years, and 100% had stage IV. A total of 373 cycles was administrated. Main grade 3/4 toxicities were neutropenia in 1.1 %, anaemia in 0.5% and thrombopenia grade 2 in 1.1%. Nausea and vomiting grade 2–3 occurred in 17.4%. Regarding efficacy, 49 out of 51 patients achieved four cycles. The overall response rate was in 84.1%, with complete response in 58.8% and partial response in 25.3%. Progression of disease occurred in 2.4%. Surgery was performed in 30 patients, and 13 had histological response (43.2%), with complete histological response in 36.6% and partial histological response in 6.6 %. The median time to progression was 13.3 months.

Conclusion

The combination of DXR with GMZ in MBC appears to be an active regimen with a favourable toxicity profile. It is well tolerated and achieved encouraging pathological response rates.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bensalem, A., Bouzid, K. A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC). Breast Cancer Res 7, P10 (2005) doi:10.1186/bcr1244

Download citation

Keywords

  • Breast Cancer
  • Doxorubicin
  • Neutropenia
  • Gemcitabine
  • Partial Response